New Zimbabwe : Political Sphere

Daviripine Vaginal Ring  RESULTS of a recently conducted study in the Sub-Saharan region, involving 15 trial sites in Malawi, Uganda, South Africa and Zimbabwe, known as A Study to Prevent Infection with a Ring for Extended Use (ASPIRE), has shown that Anti-Retroviral drugs (ARVs) can protect African women from primary Human Immune Virus (HIV) by 27%, through a virginal davirapine  ring for women. The study was conducted by the Microbicide Trials Network (MTN) and was led by Dr. Jared Baeten (University of Washington/USA) and Dr. Thesla Palanee-Phillips (Wits Reproductive Health & HIV Institute/SA). The ring is meant to be placed into the women’s vagina and would produce anti-retroviral drug, preventing women and sexually active young girls from obtaining   HIV/AIDS when sleeping with an infected partner. According to the medical officer/sub-investigator of the Aspire study, with the University of California San Francisco (UCSF) and also with the University of Zimbabwe